Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net (loss) income	$ (2,575,171)	$ 21,128,299
Adjustments to reconcile net (loss)/income to net cash (used in)/provided by operating activities
Depreciation of property and equipment	3,072,647	1,441,438
Amortization of intangible assets	2,780,580	1,279,078
Amortization of finance lease right-of-use assets	1,627,163	1,518,276
Loss on disposal of assets	153,469	0
Deferred tax asset	(1,289,797)	0
Loss (gain) on equity method investment	205,859	(30,290)
Bad debt expense	976,690	1,818,792
Stock based compensation	11,801,138	3,504,861
Gain on remeasurement of finance leases	0	(1,388,273)
Loss on liquidation of business	70,284	0
Gain on remeasurement of warrant liabilities	0	(2,969,017)
Changes in operating assets and liabilities:
Accounts receivable	(15,407,684)	4,310,990
Prepaid expenses and other current assets	(223,468)	(3,173,647)
Other assets	86,334	2,128,320
Accounts payable	(14,901,225)	(2,927,492)
Accrued liabilities	1,198,399	3,545,642
Net cash (used in) provided by operating activities	(12,424,782)	30,186,977
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of property and equipment	(3,559,656)	(941,655)
Acquisition of intangibles	(1,931,602)	(1,016,430)
Acquisition of businesses	(20,203,464)	0
Proceeds from disposal of property and equipment	277,238	0
Net cash used in investing activities	(25,417,484)	(1,958,085)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from revolving credit line	0	1,000,000
Repayments of notes payable	(247,707)	(287,998)
Due to seller	(2,556,188)	(877,088)
Noncontrolling interest contributions	0	2,063,000
Proceeds from exercise of stock options	1,123,295	1,153,410
Common stock repurchased	0	(497,899)
Equity costs	0	(19,570)
Payments on obligations under finance lease	(1,510,522)	(1,411,565)
Net cash (used in) provided by financing activities	(3,191,122)	1,122,290
Effect of exchange rate changes on cash and cash equivalents	685,076	4,571
Net (decrease) increase in cash and restricted cash	(40,348,312)	29,355,753
Cash and restricted cash at beginning of period	164,109,074	179,105,730
Cash and restricted cash at end of period	123,760,762	208,461,483
Supplemental disclosure of cash and non-cash transactions:
Cash paid for interest	126,770	129,363
Cash paid for interest on finance lease liabilities	259,051	222,649
Cash paid for income taxes	4,223,810	761,839
Right-of-use assets obtained in exchange for lease liabilities	1,538,961	2,192,946
Fixed assets acquired in exchange for notes payable	623,017	0
Reconciliation of cash and restricted cash
Cash	109,159,519	198,138,395
Restricted cash	14,601,243	10,323,088
Total cash and restricted cash shown in statement of cash flows	123,760,762	208,461,483
Ambulnz FMC NA
Supplemental disclosure of cash and non-cash transactions:
Acquisition of remaining Ambulnz-FMC North America, LLC. through Due to seller and issuance of stock	7,000,000	0
Cardiac RMS LLC
Supplemental disclosure of cash and non-cash transactions:
Acquisition of remaining Ambulnz-FMC North America, LLC. through Due to seller and issuance of stock	$ 1,000,000	$ 0